NR5A2 and hepatitis A virus infection: Specific pharmacological inhibition of LRH-1 resulted in reduced activation- and LRH-1-induced FasL expression and cytotoxicity in T cells, and inhibited FasL-dependent liver damage in the context of experimental hepatitis in vivo.